| Literature DB >> 26425038 |
Seung Soo Yoo1, Sook Kyung Do2, Jin Eun Choi2, Shin Yup Lee1, Jaehee Lee1, Seung Ick Cha1, Chang Ho Kim1, Jae Yong Park3.
Abstract
Short telomeres are known as one of the risk factors for human cancers. The present study was conducted to evaluate the association between 6 polymorphisms, which were related with short telomere length in the Korean population, and lung cancer risk using 1,100 cases and 1,096 controls. Among the 6 polymorphisms, TERT rs2853669 was significantly associated with increased lung cancer risk under a recessive model (odds ratio [OR]=1.38, 95% confidence interval [CI]=1.05-1.81, P=0.02). The effect of rs2853669 on lung cancer risk was significant in younger individuals (OR=1.73, 95% CI=1.18-2.54, P=0.005) and adenocarcinoma (OR=1.50, 95% CI=1.07-2.07, P=0.02). Our results suggest that a common functional promoter polymorphism, TERT rs2853669, may influence both telomere length and lung cancer risk in the Korean population.Entities:
Keywords: Lung Cancer Risk; Polymorphism; TERT; Telomere Length
Mesh:
Substances:
Year: 2015 PMID: 26425038 PMCID: PMC4575930 DOI: 10.3346/jkms.2015.30.10.1423
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Characteristics of the study population
| Variable | Cases (n = 1,100) | Controls (n = 1,096) | |
|---|---|---|---|
| Age (yr) | |||
| Mean ± SD | 61.4 ± 8.7 | 60.8 ± 7.4 | 0.12* |
| Gender | |||
| Male | 738 (67.1) | 736 (67.2) | 0.98† |
| Female | 362 (32.9) | 360 (32.8) | |
| Smoking status | |||
| Current | 520 (47.3) | 415 (37.9) | < 0.001† |
| Former | 267 (24.3) | 287 (26.2) | |
| Never | 313 (28.5) | 394 (35.9) | |
| Pack-years‡ | |||
| Mean ± SD | 38.7 ± 20.4 | 30.5 ± 17.4 | < 0.001* |
| Histologic type | |||
| Squamous cell carcinoma | 404 (36.7) | ||
| Adenocarcinoma | 507 (46.1) | ||
| Large cell carcinoma | 21 (1.9) | ||
| Small cell lung cancer | 148 (13.5) | ||
| NSCLC-NOS | 20 (1.8) | ||
| Stage | |||
| I | 236 (21.5) | ||
| II | 67 (6.1) | ||
| III | 361 (32.8) | ||
| IV | 436 (39.6) |
Numbers in parenthesis, column percentage. *t-test; †chi-square test; ‡in current and former smokers. SD, standard deviation; NSCLC-NOS, Non-small cell lung cancer, not otherwise specified.
Genotype frequencies of polymorphisms in lung cancer cases and controls
| Polymorphism/genotype | Cases* (%) | Controls* (%) | Adjusted OR (95% CI)‡ | q value | ||
|---|---|---|---|---|---|---|
| rs2853669 T > C | ||||||
| TT | 478 (43.8) | 485 (44.9) | 0.11 | 1.00 | ||
| TC | 477 (43.7) | 490 (45.4) | 0.99 (0.82-1.18) | 0.96 | 0.85 | |
| CC | 137 (12.5) | 105 (9.7) | 1.37 (1.03-1.83) | 0.03 | 0.18 | |
| TT+TC | 955 (87.5) | 975 (90.3) | 0.04 | 1.00 | ||
| CC | 137 (12.5) | 105 (9.7) | 1.38 (1.05-1.81) | 0.02 | 0.05 | |
| rs2736108 G > A | ||||||
| GG | 619 (57.3) | 618 (58.0) | 0.43 | 1.00 | ||
| GA | 382 (35.3) | 384 (36.0) | 0.99 (0.82-1.19) | 0.89 | 0.89 | |
| AA | 80 (7.4) | 64 (6.0) | 1.30 (0.92-1.85) | 0.14 | 0.34 | |
| GG+GA | 1001 (92.6) | 1002 (94.0) | 0.20 | 1.00 | ||
| AA | 80 (7.4) | 64 (6.0) | 1.31 (0.93-1.85) | 0.12 | 0.13 | |
| rs2736098 G > A | ||||||
| GG | 499 (45.6) | 487 (46.1) | 0.13 | 1.00 | ||
| GA | 465 (42.5) | 472 (44.7) | 0.96 (0.80-1.16) | 0.69 | 0.67 | |
| AA | 130 (11.9) | 98 (9.3) | 1.35 (1.00-1.80) | 0.05 | 0.19 | |
| GG+GA | 964 (88.1) | 959 (90.7) | 0.05 | 1.00 | ||
| AA | 130 (11.9) | 98 (9.3) | 1.37 (1.04-1.81) | 0.03 | 0.05 | |
| rs7705526 C > A | ||||||
| CC | 418 (39.6) | 433 (41.1) | 0.64 | 1.00 | ||
| CA | 474 (44.9) | 470 (44.6) | 1.05 (0.87-1.27) | 0.62 | 0.66 | |
| AA | 164 (15.5) | 150 (14.2) | 1.16 (0.89-1.50) | 0.28 | 0.54 | |
| CC+CA | 892 (84.5) | 903 (85.8) | 0.41 | 1.00 | ||
| AA | 164 (15.5) | 150 (14.2) | 1.13 (0.89-1.44) | 0.33 | 0.33 | |
| rs2293607 G > A | ||||||
| GG | 401 (37.3) | 406 (38.6) | 0.82 | 1.00 | ||
| GA | 514 (47.8) | 491 (46.6) | 1.06 (0.88-1.28) | 0.53 | 0.65 | |
| AA | 161 (15.0) | 156 (14.8) | 1.07 (0.82-1.39) | 0.63 | 0.66 | |
| GG+GA | 915 (85.0) | 897 (85.2) | 0.92 | 1.00 | ||
| AA | 161 (15.0) | 156 (14.8) | 1.03 (0.81-1.31) | 0.80 | 0.80 | |
| rs412658 C > T | ||||||
| CC | 400 (38.2) | 401 (38.4) | 0.46 | 1.00 | ||
| CT | 500 (47.8) | 478 (45.8) | 1.07 (0.89-1.29) | 0.48 | 0.65 | |
| TT | 146 (14.0) | 164 (15.7) | 0.91 (0.70-1.19) | 0.51 | 0.65 | |
| CC+CT | 900 (86.0) | 879 (84.3) | 0.26 | 1.00 | ||
| TT | 146 (14.0) | 164 (15.7) | 0.88 (0.69-1.12) | 0.31 | 0.31 |
*Numbers may not add up total number of patients due to genotype failures; †P value for chi-square test; ‡ORs, 95% CIs and their corresponding P values were calculated using multivariate regression analysis, adjusted for age, gender, and pack-years smoking. OR, odds ratio; CI, confidence interval.
Association between TERT rs2853669 and lung cancer risk according to age, gender, smoking status, tumor histology, and stage
| Variables | Cases | Controls | Adjusted OR (95% CI)* | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TT or TC | CC | TT or TC | CC | TT or TC | CC | ||||
| Age (yr) | |||||||||
| <62 | 424 (85.5) | 72 (14.5) | 500 (90.9) | 50 (9.1) | 0.01 | 1.00 | 1.73 (1.18-2.54) | 0.005§ | 0.09 |
| ≥ 62 | 531 (59.1) | 65 (10.9) | 475 (89.6) | 55 (10.4) | 0.77 | 1.00 | 1.08 (0.74-1.59) | 0.68§ | |
| Gender | |||||||||
| Male | 643 (87.8) | 89 (12.2) | 662 (90.7) | 68 (9.3) | 0.08 | 1.00 | 1.33 (0.95-1.87) | 0.09∥ | 0.79 |
| Female | 312 (86.7) | 48 (13.3) | 313 (89.4) | 37 (10.6) | 0.26 | 1.44 (0.91-2.29) | 0.12∥ | ||
| Smoking status | |||||||||
| Never | 264 (84.9) | 47 (15.1) | 344 (89.6) | 40 (10.4) | 0.06 | 1.00 | 1.47 (0.93-2.32) | 0.10¶ | 0.69 |
| Ever | 691 (88.5) | 90 (11.5) | 631 (90.7) | 65 (9.3) | 0.17 | 1.00 | 1.31 (0.94-1.84) | 0.11¶ | |
| Histology | |||||||||
| SCC | 356 (89.2) | 43 (10.8) | 975 (90.3) | 105 (9.7) | 0.55 | 1.00 | 1.16 (0.78-1.73) | 0.46** | 0.33 |
| AC | 433 (85.9) | 71 (14.1) | 975 (90.3) | 105 (9.7) | 0.01 | 1.00 | 1.50 (1.07-2.07) | 0.02** | |
| SCLC | 132 (89.2) | 16 (10.8) | 975 (90.3) | 105 (9.7) | 0.68 | 1.00 | 1.18 (0.66-2.11) | 0.57** | 0.50 |
| Stage | |||||||||
| I, II | 259 (86.9) | 39 (13.1) | 975 (90.3) | 105 (9.7) | 0.09 | 1.00 | 1.39 (0.94-2.06) | 0.10** | 0.98 |
| III, IV | 696 (87.7) | 98 (12.3) | 975 (90.3) | 105 (9.7) | 0.07 | 1.00 | 1.38 (1.03-1.86) | 0.03** | |
*ORs and 95% CIs and their corresponding P-value were calculated by unconditional logistic regression analysis; †P value for chi-square test; ‡P value for homogeneity test; §Adjusted for gender and pack-years of smoking; ∥Adjusted for age and pack-years of smoking; ¶Adjusted for age and gender; **Adjusted for age, gender, and pack-years of smoking. SCC, squamous cell carcinoma; AC, adenocarcinoma; SCLC, small cell lung cancer; OR, odds ratio; CI, confidence interval.
Locations and minor allele frequencies of polymorphisms
| Polymorphism | Gene | Region | Minor allele | Call rates (%) | MAF | |||
|---|---|---|---|---|---|---|---|---|
| Cases | Controls | Korean | JPT* | CEU* | ||||
| rs2853669 | Promoter | C | 99.3 | 98.5 | 0.37 | - | 0.38 | |
| rs2736108 | Promoter | A | 98.3 | 97.3 | 0.26 | 0.17 | 0.35 | |
| rs2736098 | Exon2 | A | 99.5 | 96.4 | 0.37 | 0.25 | 0.37 | |
| rs7705526 | Intron | A | 96.0 | 96.1 | 0.36 | - | 0.50 | |
| rs2293607 | 3' UTR | A | 97.8 | 96.1 | 0.40 | 0.33 | 0.75 | |
| rs412658 | 3' UTR | T | 95.1 | 95.2 | 0.44 | 0.33 | 0.33 | |
*Data from NCBI (http://www.ncbi.nlm.nih.gov/SNP). MAF, minor allele frequency; UTR, untranslated region.
Stratified and interaction analysis between rs2853669 and smoking status associated with lung cancer risk
| Genotype | Smoking status | |||||
|---|---|---|---|---|---|---|
| Nonsmokers | Smokers | |||||
| Cases/Controls | OR (95% CI)* | Cases/Controls | OR (95% CI)* | |||
| TT + TC | 264/344 | Reference | 691/631 | 2.82 (2.02-3.94) | 1.1 × 10-9 | |
| CC | 47/40 | 1.49 (0.94-2.35) | 0.09 | 90/65 | 3.71 (2.35-5.86) | 1.9 × 10-8 |
| 4.1 × 10-9, 2.4 × 10-8 | ||||||
| 0.02, 0.14 | ||||||
*ORs and 95% CI were calculated by unconditional logistic regression after adjusting for sex and age; †P was modified by bonferroni correction for multiple comparisons. OR, odds ratio; CI, confidence interval; Pmult, P value for multiplicative interaction term; Padd, P value for additive interaction model.